Alignment Healthcare (ALHC) reported $1.02 billion in revenue for the quarter ended June 2025, representing a year-over-year increase of 49%. EPS of $0.07 for the same period compares to -$0.13 a year ago.
The reported revenue represents a surprise of +5.75% over the Zacks Consensus Estimate of $960.06 million. With the consensus EPS estimate being -$0.07, the EPS surprise was +200%.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Alignment Healthcare performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Medical Benefit Ratio: 86.7% versus 88.5% estimated by five analysts on average.
- Health Plan Membership - Ending: 223,700 versus the four-analyst average estimate of 221,463.
- Revenues- Other: $9.09 million versus the four-analyst average estimate of $8.32 million. The reported number represents a year-over-year change of +26.3%.
- Revenues- Earned premiums: $1.01 billion versus $946.69 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +49.3% change.
View all Key Company Metrics for Alignment Healthcare here>>>
Shares of Alignment Healthcare have returned -17.1% over the past month versus the Zacks S&P 500 composite's +3.4% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Alignment Healthcare, Inc. (ALHC): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
